SK Biopharmaceuticals, a South Korean pharmaceutical company, has been awarded funding from the Korea Drug Development Fund.
The company will use the funds to support global late Phase 2 clinical trials in refractory epilepsy for its lead drug, YKP3089 in the next three years.
If Phase 2 and Phase 3 clinical trials will have good results, SK Biopharmaceuticals will be able to market the drug in 2017. YKP3089 is designed to have a broad spectrum of action in animal models of epilepsy and seizure disorders. It is also active in other models of behavioral disorders and has authorized Investigational New Drug status from the U.S. Food and Drug Administration.
Led by Dr. Jeong Woo Cho, Vice President for Drug Development Business, SK Biopharmaceuticals focuses on discovery and development of new drugs as well as providing custom services for the manufacture and sales of active pharmaceutical ingredients as well as producing intermediates of drugs for major companies, including Pfizer and Roche in their factories in Korea. Launched in April 2011 after being spun out from SK Holdings, the company has a preclinical research and development center located in Daejeon, South Korea, and its business development and clinical research center in New Jersey for the clinical development of its assets in the areas of epilepsy, neuropathic pain, depression, irritable bowel syndrome, and Parkinson’s disease.